Frailty, General Anesthetic Drug Adverse Reaction, Gynecologic Cancer, Neuromuscular Blockade, Surgical Complication
Conditions
Keywords
neuromuscular blocking agents, frailty, gynecologic oncology, surgery, anesthetic complications
Brief summary
Frailty among patients undergoing surgery is strongly associated with an elevated risk of adverse perioperative outcomes, heightened incidence of postoperative complications, increased mortality rates, and prolonged hospital length of stay. Our focus centers on investigating the frailty index in the context of complications experienced by patients undergoing oncologic gynecology surgery. The principal objective of this research is to elucidate the extent to which residual neuromuscular blocking agents are linked to frailty.
Detailed description
Among patients undergoing oncologic gynecological procedures, such as those for vulvar cancer, endometrial cancer, and ovarian cancer, the incidence of frailty has been observed to range from 14% to 45%. Frailty directly influences the metabolism of anesthetic agents and intraoperative management. Furthermore, the prevalence of residual neuromuscular blocking agents following surgery can be as high as 26% to 53%. No prior research has investigated the correlation between residual muscle relaxants and frailty in gynecologic oncology patients. This study is designed to assess the prevalence of residual muscle relaxants in these patients with frailty. Additionally, data on the incidence of frailty and its impact on postoperative outcomes and prognosis in patients undergoing gynecologic oncology surgery will be collected and reported.
Interventions
DIAGNOSTIC_TESTTrain of four nerve stimulator
Patient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.
Sponsors
Mahidol University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Train of four nerve stimulation
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>,= 18 years * Patients undergoing elective gynecologic-oncology surgery
Exclusion criteria
* Unable to communicate Thai * Unable to understand the questionnaire * Preexisting neuromuscular disease * Preexisting disease involved wrist that may affect the nerve stimulator examination
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of residual neuromuscular blockade | 0-30 minute after surgery | Incidence of residual neuromuscular blockade with the relation of frailty after gynecologic oncology surgery |
| Incidence of frailty | 0 - 24 hours preoperative | Incidence of frailty in patients undergoing gynecologic oncology surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of vasopressor usage | Throughout Intraoperative period, an average 3-5 hours to 24 hours postoperative | Rate of vasopressor usage eg. ephedrine, norepinephrine |
| Length of hospital stay | Through study completion, an average of 1 year, an average 3 - 5 days | Total number of days of hospital stay |
| Rate of intensive care unit admission | 0 - 24 hours postoperative | Number of patients who require intensive care unit admission after surgery |
| Anesthetic technique used | Throughout Intraoperative period, an average 3-5 hours | Anesthetic technique used in patients undergoing gynecologic oncology surgery |
| Rate of postoperative mechanical ventilation | 0 - 24 hours postoperative | Number of patients who require mechanical ventilation postoperative |
| Rate of postoperative pulmonary complications | 3 days after operation | Number of patients who have postoperative pulmonary complications eg. prolonged intubation, atelectasis, pneumonia etc. |
| Mortality rate | 30 days after operation | Number of patients who died after surgery |
| Rate of re-intubation | 0 - 24 hours postoperative | Number of patients who require re-intubation |
| Rate of blood transfusion | Throughout Intraoperative period, an average 3-5 hours to 24 hours postoperative | Quantity of units blood transfusion |
Countries
Thailand
Contacts
Primary ContactPatchareya Nivatpumin, M.D.
Backup ContactJitsupa Nithiuthai, M.D.
Outcome results
None listed